NCI-2019-07941

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This randomized study is about comparing two treatments for a type of lung cancer called non-small cell lung cancer (NSCLC). One treatment is a combination of two drugs: AZD9291 (also known as Osimertinib) and Bevacizumab. The other treatment is just AZD9291 alone. The study wants to see which treatment works better as the first treatment for patients with NSCLC that has spread to other parts of the body. The goal is to find the most effective treatment for this type of lung cancer with an EGFR mutation.

EGFR: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

mutation: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

NSCLC: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04181060

Clinical Trial Site: Einstein/Sinai

To see all available clinical trials click here.